Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease?
Background This investigation aimed to determine whether patients presenting to a psoriatic arthritis (PsA) clinic early in the course of the disease had less severe disease at presentation, and whether disease duration at presentation predicts progression of joint damage. Methods Patients followed...
Gespeichert in:
Veröffentlicht in: | Annals of the rheumatic diseases 2011-12, Vol.70 (12), p.2152-2154 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 2154 |
---|---|
container_issue | 12 |
container_start_page | 2152 |
container_title | Annals of the rheumatic diseases |
container_volume | 70 |
creator | Gladman, Dafna D Thavaneswaran, Arane Chandran, Vinod Cook, Richard J |
description | Background This investigation aimed to determine whether patients presenting to a psoriatic arthritis (PsA) clinic early in the course of the disease had less severe disease at presentation, and whether disease duration at presentation predicts progression of joint damage. Methods Patients followed prospectively in a specialised clinic were divided into those first seen within 2 years of diagnosis (group 1) and those seen with more than 2 years of disease (group 2). The groups were compared with regard to demographics and disease characteristics at presentation. A multivariate analysis using a negative binomial model was conducted to determine whether patients with early disease had less progression of joint damage. Results 436 patients were identified in group 1 and 641 patients in group 2. Patients in group 2 were older, had longer duration of psoriasis and PsA, more joint damage and were less likely to be treated with disease-modifying antirheumatic drugs, but had similar level of education and degree of psoriasis severity. After adjusting for age, sex, education level, clinical joint damage at first visit and treatment, group 2 had significantly greater rate of clinical damage progression compared with group 1. Conclusions Disease progression is more marked in patients presenting with established disease of more than 2 years' duration. These results suggest that patients with PsA should be treated earlier in the course of their disease. |
doi_str_mv | 10.1136/ard.2011.150938 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_902331370</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>902331370</sourcerecordid><originalsourceid>FETCH-LOGICAL-b427t-2bf0f69c1c3078a0702ddcd5896704e842dd97ad7e701d7c5e96ae72bd9f3c603</originalsourceid><addsrcrecordid>eNqF0VFrFDEQAOAgFntWn32TgIhQ2Osk2U12n0RObQu1ItW-hmwy6-Xc2z2THNp_b5a9VvDFl4TJfBkmGUJeMFgyJuSZCW7JgbElq6AR9SOyYKWsCw4SHpMFAIiibKQ6Jk9j3OQQalY_IcecNdlxtSDD-5HuTPI4pEh_-bSmuzgGn08sNSGtg08-J9ZZBYxZUTShv6OdCUhbTAkDTWsz5GWMeI_88J32Zsr5KYPU-Ygm4ttn5KgzfcTnh_2EfPv44evqorj6fH65endVtCVXqeBtB51sLLMCVG1AAXfOuqrOb4ES6zKHjTJOoQLmlK2wkQYVb13TCStBnJA3c91dGH_uMSa99dFi35sBx33UDXAhmFCTfPWP3Iz7MOTmNFNK1bIGrrI6m5UNY4wBO70LfmvCnWagp0noPAk9TULPk8g3Xh7q7tstugd___UZvD4AE63pu2AG6-NfV6qKgZhcMTsfE_5-yJvwQ0slVKWvb1f60_X5zZdbeaOb7E9n3243_-3yD4D4rfc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1777868027</pqid></control><display><type>article</type><title>Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease?</title><source>MEDLINE</source><source>BMJ Journals - NESLi2</source><creator>Gladman, Dafna D ; Thavaneswaran, Arane ; Chandran, Vinod ; Cook, Richard J</creator><creatorcontrib>Gladman, Dafna D ; Thavaneswaran, Arane ; Chandran, Vinod ; Cook, Richard J</creatorcontrib><description>Background This investigation aimed to determine whether patients presenting to a psoriatic arthritis (PsA) clinic early in the course of the disease had less severe disease at presentation, and whether disease duration at presentation predicts progression of joint damage. Methods Patients followed prospectively in a specialised clinic were divided into those first seen within 2 years of diagnosis (group 1) and those seen with more than 2 years of disease (group 2). The groups were compared with regard to demographics and disease characteristics at presentation. A multivariate analysis using a negative binomial model was conducted to determine whether patients with early disease had less progression of joint damage. Results 436 patients were identified in group 1 and 641 patients in group 2. Patients in group 2 were older, had longer duration of psoriasis and PsA, more joint damage and were less likely to be treated with disease-modifying antirheumatic drugs, but had similar level of education and degree of psoriasis severity. After adjusting for age, sex, education level, clinical joint damage at first visit and treatment, group 2 had significantly greater rate of clinical damage progression compared with group 1. Conclusions Disease progression is more marked in patients presenting with established disease of more than 2 years' duration. These results suggest that patients with PsA should be treated earlier in the course of their disease.</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/ard.2011.150938</identifier><identifier>PMID: 21914627</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><subject>Adult ; Age Factors ; Antirheumatic Agents - therapeutic use ; Arthritis, Psoriatic - drug therapy ; Biological and medical sciences ; Dermatology ; Disease Progression ; Diseases of the osteoarticular system ; Diseases of the spine ; Early Diagnosis ; Education ; Epidemiologic Methods ; Female ; Humans ; Inflammatory joint diseases ; Male ; Medical sciences ; Patient Selection ; Prognosis ; Psoriasis ; Psoriasis. Parapsoriasis. Lichen ; Psoriatic arthritis ; Secondary Prevention ; Time Factors ; Treatment Outcome</subject><ispartof>Annals of the rheumatic diseases, 2011-12, Vol.70 (12), p.2152-2154</ispartof><rights>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>2015 INIST-CNRS</rights><rights>Copyright: 2011 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b427t-2bf0f69c1c3078a0702ddcd5896704e842dd97ad7e701d7c5e96ae72bd9f3c603</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://ard.bmj.com/content/70/12/2152.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://ard.bmj.com/content/70/12/2152.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,780,784,3196,23571,27924,27925,77600,77631</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24751037$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21914627$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gladman, Dafna D</creatorcontrib><creatorcontrib>Thavaneswaran, Arane</creatorcontrib><creatorcontrib>Chandran, Vinod</creatorcontrib><creatorcontrib>Cook, Richard J</creatorcontrib><title>Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease?</title><title>Annals of the rheumatic diseases</title><addtitle>Ann Rheum Dis</addtitle><description>Background This investigation aimed to determine whether patients presenting to a psoriatic arthritis (PsA) clinic early in the course of the disease had less severe disease at presentation, and whether disease duration at presentation predicts progression of joint damage. Methods Patients followed prospectively in a specialised clinic were divided into those first seen within 2 years of diagnosis (group 1) and those seen with more than 2 years of disease (group 2). The groups were compared with regard to demographics and disease characteristics at presentation. A multivariate analysis using a negative binomial model was conducted to determine whether patients with early disease had less progression of joint damage. Results 436 patients were identified in group 1 and 641 patients in group 2. Patients in group 2 were older, had longer duration of psoriasis and PsA, more joint damage and were less likely to be treated with disease-modifying antirheumatic drugs, but had similar level of education and degree of psoriasis severity. After adjusting for age, sex, education level, clinical joint damage at first visit and treatment, group 2 had significantly greater rate of clinical damage progression compared with group 1. Conclusions Disease progression is more marked in patients presenting with established disease of more than 2 years' duration. These results suggest that patients with PsA should be treated earlier in the course of their disease.</description><subject>Adult</subject><subject>Age Factors</subject><subject>Antirheumatic Agents - therapeutic use</subject><subject>Arthritis, Psoriatic - drug therapy</subject><subject>Biological and medical sciences</subject><subject>Dermatology</subject><subject>Disease Progression</subject><subject>Diseases of the osteoarticular system</subject><subject>Diseases of the spine</subject><subject>Early Diagnosis</subject><subject>Education</subject><subject>Epidemiologic Methods</subject><subject>Female</subject><subject>Humans</subject><subject>Inflammatory joint diseases</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Patient Selection</subject><subject>Prognosis</subject><subject>Psoriasis</subject><subject>Psoriasis. Parapsoriasis. Lichen</subject><subject>Psoriatic arthritis</subject><subject>Secondary Prevention</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqF0VFrFDEQAOAgFntWn32TgIhQ2Osk2U12n0RObQu1ItW-hmwy6-Xc2z2THNp_b5a9VvDFl4TJfBkmGUJeMFgyJuSZCW7JgbElq6AR9SOyYKWsCw4SHpMFAIiibKQ6Jk9j3OQQalY_IcecNdlxtSDD-5HuTPI4pEh_-bSmuzgGn08sNSGtg08-J9ZZBYxZUTShv6OdCUhbTAkDTWsz5GWMeI_88J32Zsr5KYPU-Ygm4ttn5KgzfcTnh_2EfPv44evqorj6fH65endVtCVXqeBtB51sLLMCVG1AAXfOuqrOb4ES6zKHjTJOoQLmlK2wkQYVb13TCStBnJA3c91dGH_uMSa99dFi35sBx33UDXAhmFCTfPWP3Iz7MOTmNFNK1bIGrrI6m5UNY4wBO70LfmvCnWagp0noPAk9TULPk8g3Xh7q7tstugd___UZvD4AE63pu2AG6-NfV6qKgZhcMTsfE_5-yJvwQ0slVKWvb1f60_X5zZdbeaOb7E9n3243_-3yD4D4rfc</recordid><startdate>20111201</startdate><enddate>20111201</enddate><creator>Gladman, Dafna D</creator><creator>Thavaneswaran, Arane</creator><creator>Chandran, Vinod</creator><creator>Cook, Richard J</creator><general>BMJ Publishing Group Ltd and European League Against Rheumatism</general><general>BMJ Publishing Group</general><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20111201</creationdate><title>Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease?</title><author>Gladman, Dafna D ; Thavaneswaran, Arane ; Chandran, Vinod ; Cook, Richard J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b427t-2bf0f69c1c3078a0702ddcd5896704e842dd97ad7e701d7c5e96ae72bd9f3c603</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Age Factors</topic><topic>Antirheumatic Agents - therapeutic use</topic><topic>Arthritis, Psoriatic - drug therapy</topic><topic>Biological and medical sciences</topic><topic>Dermatology</topic><topic>Disease Progression</topic><topic>Diseases of the osteoarticular system</topic><topic>Diseases of the spine</topic><topic>Early Diagnosis</topic><topic>Education</topic><topic>Epidemiologic Methods</topic><topic>Female</topic><topic>Humans</topic><topic>Inflammatory joint diseases</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Patient Selection</topic><topic>Prognosis</topic><topic>Psoriasis</topic><topic>Psoriasis. Parapsoriasis. Lichen</topic><topic>Psoriatic arthritis</topic><topic>Secondary Prevention</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gladman, Dafna D</creatorcontrib><creatorcontrib>Thavaneswaran, Arane</creatorcontrib><creatorcontrib>Chandran, Vinod</creatorcontrib><creatorcontrib>Cook, Richard J</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gladman, Dafna D</au><au>Thavaneswaran, Arane</au><au>Chandran, Vinod</au><au>Cook, Richard J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease?</atitle><jtitle>Annals of the rheumatic diseases</jtitle><addtitle>Ann Rheum Dis</addtitle><date>2011-12-01</date><risdate>2011</risdate><volume>70</volume><issue>12</issue><spage>2152</spage><epage>2154</epage><pages>2152-2154</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>Background This investigation aimed to determine whether patients presenting to a psoriatic arthritis (PsA) clinic early in the course of the disease had less severe disease at presentation, and whether disease duration at presentation predicts progression of joint damage. Methods Patients followed prospectively in a specialised clinic were divided into those first seen within 2 years of diagnosis (group 1) and those seen with more than 2 years of disease (group 2). The groups were compared with regard to demographics and disease characteristics at presentation. A multivariate analysis using a negative binomial model was conducted to determine whether patients with early disease had less progression of joint damage. Results 436 patients were identified in group 1 and 641 patients in group 2. Patients in group 2 were older, had longer duration of psoriasis and PsA, more joint damage and were less likely to be treated with disease-modifying antirheumatic drugs, but had similar level of education and degree of psoriasis severity. After adjusting for age, sex, education level, clinical joint damage at first visit and treatment, group 2 had significantly greater rate of clinical damage progression compared with group 1. Conclusions Disease progression is more marked in patients presenting with established disease of more than 2 years' duration. These results suggest that patients with PsA should be treated earlier in the course of their disease.</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd and European League Against Rheumatism</pub><pmid>21914627</pmid><doi>10.1136/ard.2011.150938</doi><tpages>3</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0003-4967 |
ispartof | Annals of the rheumatic diseases, 2011-12, Vol.70 (12), p.2152-2154 |
issn | 0003-4967 1468-2060 |
language | eng |
recordid | cdi_proquest_miscellaneous_902331370 |
source | MEDLINE; BMJ Journals - NESLi2 |
subjects | Adult Age Factors Antirheumatic Agents - therapeutic use Arthritis, Psoriatic - drug therapy Biological and medical sciences Dermatology Disease Progression Diseases of the osteoarticular system Diseases of the spine Early Diagnosis Education Epidemiologic Methods Female Humans Inflammatory joint diseases Male Medical sciences Patient Selection Prognosis Psoriasis Psoriasis. Parapsoriasis. Lichen Psoriatic arthritis Secondary Prevention Time Factors Treatment Outcome |
title | Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease? |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T04%3A00%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Do%20patients%20with%20psoriatic%20arthritis%20who%20present%20early%20fare%20better%20than%20those%20presenting%20later%20in%20the%20disease?&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Gladman,%20Dafna%20D&rft.date=2011-12-01&rft.volume=70&rft.issue=12&rft.spage=2152&rft.epage=2154&rft.pages=2152-2154&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/ard.2011.150938&rft_dat=%3Cproquest_cross%3E902331370%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1777868027&rft_id=info:pmid/21914627&rfr_iscdi=true |